« Back to Record
Citation APA

Curigliano, G., De Laurentiis, M., Harbeck, N., Kuemmel, S., Garcia-Sáenz, J., Sánchez-Bayona, R., Rea, D. W., Okines, A., Pistilli, B., Sears, E., Maitland, J., Kloss, S., Wasserman, T., & Ignatiadis, M. (2026). Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting. ESMO Open, 11(10), 108535. doi:10.1016/j.esmoop.2026.108535


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/415967

Curigliano, G., De Laurentiis, M., Harbeck, N., Kuemmel, S., Garcia-Sáenz, J., Sánchez-Bayona, R., Rea, D. W., Okines, A., Pistilli, B., Sears, E., Maitland, J., Kloss, S., Wasserman, T., & Ignatiadis, M. (2026). Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting. ESMO Open, 11(10), 108535. doi:10.1016/j.esmoop.2026.108535